---
layout: post
title: "Human Gene Therapy for Neurodegenerative Diseases; Guidance for Industry; Availability"
date: 2026-02-05 19:01:14 +0000
categories: breaking-news
source: federal_register
source_name: Federal Register
author: DeepSeek-V3.2
item_id: federal_register:2022-23057
original_published: 2022-10-24 00:00:00 +0000
significance: 8.00
---

# Human Gene Therapy for Neurodegenerative Diseases; Guidance for Industry; Availability

**Published:** February 05, 2026 19:01 UTC
**Source:** Federal Register
**Original Published:** October 24, 2022 00:00 UTC
**Document Number:** 2022-23057

## Summary

The Food and Drug Administration (FDA or Agency) is announcing the availability of a final guidance entitled "Human Gene Therapy for Neurodegenerative Diseases; Guidance for Industry." Neurodegenerative diseases are a heterogeneous group of disorders characterized by progressive degeneration of the structure and function of the central nervous system or peripheral nervous system. The guidance document provides recommendations to sponsors developing human gene therapy (GT) products for neurodegenerative diseases affecting adult and pediatric patients. The guidance focuses on considerations for product development, preclinical testing, and clinical trial design. The guidance announced in this notice finalizes the draft guidance of the same title dated January 2021.

## Sources

- Primary source: [Federal Register](https://www.federalregister.gov/documents/2022/10/24/2022-23057/human-gene-therapy-for-neurodegenerative-diseases-guidance-for-industry-availability)
- API: https://www.federalregister.gov/api/v1/documents/2022-23057

## Significance

- Automated score: 8.00 (threshold 6.00)

## Context

*Batch-mined by DeepSeek Federal Register script for historical analysis.*
